OXBL Stock Overview
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£4.14 |
| 52 Week High | UK£4.46 |
| 52 Week Low | UK£1.64 |
| Beta | 1.05 |
| 11 Month Change | -1.31% |
| 3 Month Change | 17.39% |
| 1 Year Change | 128.71% |
| 33 Year Change | -69.60% |
| 5 Year Change | -27.20% |
| Change since IPO | 46.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| OXBL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.3% | -5.2% | 0.8% |
| 1Y | 128.7% | -20.1% | 6.6% |
Return vs Industry: OXBL exceeded the UK Biotechs industry which returned -18.9% over the past year.
Return vs Market: OXBL exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| OXBL volatility | |
|---|---|
| OXBL Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OXBL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: OXBL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 834 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product.
Oxford Biomedica plc Fundamentals Summary
| OXBL fundamental statistics | |
|---|---|
| Market cap | UK£434.61m |
| Earnings (TTM) | -UK£142.02m |
| Revenue (TTM) | UK£97.28m |
4.5x
P/S Ratio-3.1x
P/E RatioIs OXBL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXBL income statement (TTM) | |
|---|---|
| Revenue | UK£97.28m |
| Cost of Revenue | UK£61.54m |
| Gross Profit | UK£35.74m |
| Other Expenses | UK£177.76m |
| Earnings | -UK£142.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 36.74% |
| Net Profit Margin | -145.98% |
| Debt/Equity Ratio | 55.8% |
How did OXBL perform over the long term?
See historical performance and comparison